



# Market Announcement

24 October 2018

---

## ResApp Health Limited (ASX: RAP) – Suspension from Official Quotation

### Description

The securities of ResApp Health Limited ('RAP') will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAP, pending the release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis.

### Issued by

**Dale Allen**

Senior Adviser, Listings Compliance (Perth)

24 October 2018

Shannon Nicholson  
Principal Adviser, Listings Compliance  
Level 40, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

Dear Shannon

**RESAPP HEALTH LIMITED – VOLUNTARY SUSPENSION REQUEST**

Further to the request on 22 October 2018 for the securities of ResApp Health Limited (“**Company**”) to be placed in trading halt, the Company hereby requests that the securities be placed in voluntary suspension in accordance with ASX Listing Rule 17.2 pending release of an announcement regarding its US SMARTCOUGH-C-2 study results and analysis.

The Company requests that the voluntary suspension end on the date the anticipated announcement referred to above is released to the market which the Company anticipates will occur by Monday 29 October 2018.

The Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the suspension.

Yours faithfully



**Nicki Farley**  
**Company Secretary**  
**ResApp Health Limited**